Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
AI continues to draw massive capital and new use cases in biopharma: Take Prometheus’ $12 billion raise to build “artificial general engineers,” or Abridge’s new partnerships with Eli Lilly and Nvidia, which aims in part to optimize the clinical trial recruitment process.
Plus, a nonprofit buys a shelved drug for a pediatric leukemia with plans to distribute it for free.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
